4-Benzyl-9-Methyl-1-oxa-4,9-diazaspiro[5.5]undecane
- $328 - $836.4
- Product name: 4-Benzyl-9-Methyl-1-oxa-4,9-diazaspiro[5.5]undecane
- CAS: 1352925-36-0
- MF: C16H24N2O
- MW: 260.37
- EINECS:
- MDL Number:
- Synonyms:4-Benzyl-9-Methyl-1-oxa-4,9-diazaspiro[5.5]undecane;1-Oxa-4,9-diazaspiro[5.5]undecane, 9-methyl-4-(phenylmethyl)-
4 prices
Selected condition:
Brand
- Alichem
- Chemenu
- Crysdot
Package
- 250mg
- 1g
- ManufacturerAlichem
- Product number1352925360
- Product description4-Benzyl-9-methyl-1-oxa-4,9-diazaspiro[5.5]undecane
- Packaging1g
- Price$836.4
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM139186
- Product description4-Benzyl-9-methyl-1-oxa-4,9-diazaspiro[5.5]undecane 95%
- Packaging1g
- Price$767
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11287088
- Product description4-Benzyl-9-methyl-1-oxa-4,9-diazaspiro[5.5]undecane 95+%
- Packaging250mg
- Price$328
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11287088
- Product description4-Benzyl-9-methyl-1-oxa-4,9-diazaspiro[5.5]undecane 95+%
- Packaging1g
- Price$820
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Alichem | 1352925360 | 4-Benzyl-9-methyl-1-oxa-4,9-diazaspiro[5.5]undecane | 1g | $836.4 | 2021-12-16 | Buy |
Chemenu | CM139186 | 4-Benzyl-9-methyl-1-oxa-4,9-diazaspiro[5.5]undecane 95% | 1g | $767 | 2021-12-16 | Buy |
Crysdot | CD11287088 | 4-Benzyl-9-methyl-1-oxa-4,9-diazaspiro[5.5]undecane 95+% | 250mg | $328 | 2021-12-16 | Buy |
Crysdot | CD11287088 | 4-Benzyl-9-methyl-1-oxa-4,9-diazaspiro[5.5]undecane 95+% | 1g | $820 | 2021-12-16 | Buy |
Properties
Safety Information
Symbol(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|